$CRIS
CURIS INC

2023 Q4 Form 10-Q Financial Statement

#000110820523000074 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.696M $2.833M
YoY Change -6.62% 0.28%
Cost Of Revenue $54.00K $60.00K
YoY Change -23.94% -3.23%
Gross Profit $2.642M $2.770M
YoY Change -6.18% 0.25%
Gross Profit Margin 98.0% 97.78%
Selling, General & Admin $4.877M $4.760M
YoY Change 12.63% 4.48%
% of Gross Profit 184.6% 171.84%
Research & Development $9.964M $10.38M
YoY Change 14.45% -4.0%
% of Gross Profit 377.14% 374.73%
Depreciation & Amortization $65.00K $60.00K
YoY Change -29.35% -1.64%
% of Gross Profit 2.46% 2.17%
Operating Expenses $14.84M $10.38M
YoY Change 13.85% -4.0%
Operating Profit -$12.20M -$12.37M
YoY Change 19.36% -1.89%
Interest Expense $665.0K $810.0K
YoY Change 22.69% 141.79%
% of Operating Profit
Other Income/Expense, Net -$178.0K $187.0K
YoY Change -89.22% -127.18%
Pretax Income -$11.71M -$12.18M
YoY Change 3.38% -8.38%
Income Tax
% Of Pretax Income
Net Earnings -$11.71M -$12.18M
YoY Change 3.38% -8.37%
Net Earnings / Revenue -434.42% -429.97%
Basic Earnings Per Share -$2.13
Diluted Earnings Per Share -$2.03 -$2.13
COMMON SHARES
Basic Shares Outstanding 5.883M shares 117.7M shares
Diluted Shares Outstanding 5.721M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.33M $68.50M
YoY Change -34.21% -30.59%
Cash & Equivalents $26.68M $24.47M
Short-Term Investments $29.65M $44.00M
Other Short-Term Assets $1.780M $2.100M
YoY Change -49.45% -49.3%
Inventory
Prepaid Expenses
Receivables $2.794M $2.848M
Other Receivables $0.00 $0.00
Total Short-Term Assets $60.91M $73.43M
YoY Change -33.88% -30.54%
LONG-TERM ASSETS
Property, Plant & Equipment $434.0K $497.0K
YoY Change -37.01% -36.28%
Goodwill $9.000M $8.982M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.358M $3.124M
YoY Change 66.07% 54.5%
Total Long-Term Assets $16.37M $16.55M
YoY Change -2.12% -3.43%
TOTAL ASSETS
Total Short-Term Assets $60.91M $73.43M
Total Long-Term Assets $16.37M $16.55M
Total Assets $77.28M $89.98M
YoY Change -29.0% -26.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.172M $5.221M
YoY Change -0.66% -9.29%
Accrued Expenses $9.040M $7.225M
YoY Change 59.18% 4.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.52M $13.71M
YoY Change 34.99% -0.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $44.10M $46.70M
YoY Change -15.66% -12.49%
Total Long-Term Liabilities $44.10M $46.70M
YoY Change -15.66% -12.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.52M $13.71M
Total Long-Term Liabilities $44.10M $46.70M
Total Liabilities $57.61M $60.38M
YoY Change -7.52% -10.02%
SHAREHOLDERS EQUITY
Retained Earnings -$1.200B -$1.200B
YoY Change 9.09% 9.09%
Common Stock $1.216B $1.214B
YoY Change 1.68% 1.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.67M $29.59M
YoY Change
Total Liabilities & Shareholders Equity $77.28M $89.98M
YoY Change -29.0% -26.76%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.71M -$12.18M
YoY Change 3.38% -8.37%
Depreciation, Depletion And Amortization $65.00K $60.00K
YoY Change -29.35% -1.64%
Cash From Operating Activities -$10.18M -$8.180M
YoY Change -16.99% -37.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $14.52M $180.0K
YoY Change 319.17% -95.87%
Cash From Investing Activities $14.52M $180.0K
YoY Change 319.17% -95.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.120M 12.56M
YoY Change 52.74% 169.41%
NET CHANGE
Cash From Operating Activities -10.18M -8.180M
Cash From Investing Activities 14.52M 180.0K
Cash From Financing Activities -2.120M 12.56M
Net Change In Cash 2.212M 4.560M
YoY Change -121.7% -209.69%
FREE CASH FLOW
Cash From Operating Activities -$10.18M -$8.180M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$10.18M -$8.180M
YoY Change -16.99% -37.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
11390625 shares
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
60000 usd
CY2022Q3 us-gaap Royalty Expense
RoyaltyExpense
62000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10380000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10813000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4761000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4556000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
15431000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13294000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
101000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
76000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12080000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13218000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1395000 usd
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
0.05
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5885313 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5885313 shares
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
15201000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
806000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
335000 usd
CY2023Q3 cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
619000 usd
CY2022Q3 cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
1023000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
187000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-688000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13294000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.82
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5720789 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5720789 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5131904 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5131904 shares
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
8000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
195000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11559000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
36591000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1424000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
178000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1300000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13814000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1633000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
2500 shares
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
101000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29591000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
90707000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1718000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-342000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16109000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
75974000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1966000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
149000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-104000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15940000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
62045000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
700000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5594000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
76000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13294000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
55745000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35701000 usd
us-gaap Net Income Loss
NetIncomeLoss
-45343000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
191000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
141000 usd
cris Non Cash Lease Expense
NonCashLeaseExpense
999000 usd
cris Non Cash Lease Expense
NonCashLeaseExpense
840000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4452000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5008000 usd
cris Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
-336000 usd
cris Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
28000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1044000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-651000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-127000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-338000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-338000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2897000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3574000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-187000 usd
cris Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
-848000 usd
cris Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
-648000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
7453000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3274000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28248000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42069000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
64656000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
49419000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
87925000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
79395000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
416000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23269000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29560000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
185000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
149000 usd
cris Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
4301000 usd
cris Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
3557000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9698000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2255000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4719000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10254000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25012000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000 usd
CY2023Q3 cris Accrued Issuance Costs
AccruedIssuanceCosts
0 usd
CY2022Q3 cris Accrued Issuance Costs
AccruedIssuanceCosts
69000 usd
us-gaap Interest Paid Net
InterestPaidNet
2177000 usd
us-gaap Interest Paid Net
InterestPaidNet
3093000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-191000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates to treat cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company,” “Curis,” “we,” “us,” or “our.”</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company has prioritized its lead clinical stage drug candidate emavusertib, an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (“IRAK4”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the Company’s ability to execute on its overall business strategies; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company’s ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; and the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with entities managed by Oberland Capital Management, LLC (the “Purchasers”), and Lind SA LLC (the “Agent”), as collateral agent for the Purchasers.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2023, the Company had an accumulated deficit of $1.2 billion, and for the nine months ended September 30, 2023, the Company incurred a net loss of $35.7 million and used $28.2 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $68.5 million of existing cash, cash equivalents and investments at September 30, 2023 should be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development of emavusertib, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1200000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35700000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28200000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
68500000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates and AssumptionsThe preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the collectability of receivables; the carrying value of goodwill; and the value of certain investments and liabilities. Actual results may differ from such estimates. These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
500000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
600000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3157000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
43949000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
84000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
44030000 usd
cris Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
P0Y3M18D
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
66151000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
188000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
65965000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
27400000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3152000 usd
CY2023Q3 cris Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
3329000 usd
CY2022Q4 cris Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
1727000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
685000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
762000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7225000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5679000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3100000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3400000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3900000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
400000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
400000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1000000.0 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2019Q1 cris Royalty Purchase Agreement Interest Rate
RoyaltyPurchaseAgreementInterestRate
0.061
CY2019Q1 cris Royalty Purchase Agreement Transaction Fees And Closing Costs
RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts
600000 usd
CY2022Q4 cris Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
49483000 usd
cris Royalty Purchase Agreement Issuance Costs Capitalized Amortization
RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization
-127000 usd
cris Royalty Purchase Agreement Accretion Expense
RoyaltyPurchaseAgreementAccretionExpense
1968000 usd
cris Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
6479000 usd
CY2023Q3 cris Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
44845000 usd
cris Collaboration Agreement Numberof Programs Licensed
CollaborationAgreementNumberofProgramsLicensed
4 program
cris Share Based Compensation Plans
ShareBasedCompensationPlans
2 plan
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
683666 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.72
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M3D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
273202 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.27
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
515 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115987 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
66.10
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
840366 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M2D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
434527 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
62.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M8D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
840366 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
48.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
43.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.14
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9400000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1633000000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1324000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4452000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5008000 usd

Files In Submission

Name View Source Status
cris-20230930_lab.xml Edgar Link unprocessable
cris-20230930_def.xml Edgar Link unprocessable
0001108205-23-000074-index-headers.html Edgar Link pending
0001108205-23-000074-index.html Edgar Link pending
0001108205-23-000074.txt Edgar Link pending
0001108205-23-000074-xbrl.zip Edgar Link pending
cris-20230930.htm Edgar Link pending
cris-20230930.xsd Edgar Link pending
cris-9302023x10qexx31.htm Edgar Link pending
cris-9302023x10qexx311.htm Edgar Link pending
cris-9302023x10qexx312.htm Edgar Link pending
cris-9302023x10qexx321.htm Edgar Link pending
cris-9302023x10qexx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cris-20230930_pre.xml Edgar Link unprocessable
cris-20230930_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cris-20230930_cal.xml Edgar Link unprocessable